KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pfizer (PFE) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Pfizer (PFE) over the last 17 years, with Q3 2025 value amounting to $9.3 billion.

  • Pfizer's Other Non-Current Assets fell 1114.82% to $9.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $9.3 billion, marking a year-over-year decrease of 1114.82%. This contributed to the annual value of $9.8 billion for FY2024, which is 2128.14% down from last year.
  • Per Pfizer's latest filing, its Other Non-Current Assets stood at $9.3 billion for Q3 2025, which was down 1114.82% from $9.5 billion recorded in Q2 2025.
  • In the past 5 years, Pfizer's Other Non-Current Assets registered a high of $13.2 billion during Q4 2022, and its lowest value of $4.7 billion during Q2 2021.
  • In the last 5 years, Pfizer's Other Non-Current Assets had a median value of $9.8 billion in 2024 and averaged $9.6 billion.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first soared by 7141.55% in 2022, then tumbled by 2128.14% in 2024.
  • Quarter analysis of 5 years shows Pfizer's Other Non-Current Assets stood at $7.7 billion in 2021, then skyrocketed by 71.42% to $13.2 billion in 2022, then fell by 5.26% to $12.5 billion in 2023, then dropped by 21.28% to $9.8 billion in 2024, then dropped by 5.09% to $9.3 billion in 2025.
  • Its last three reported values are $9.3 billion in Q3 2025, $9.5 billion for Q2 2025, and $9.8 billion during Q1 2025.